These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19397693

  • 1. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    Winkler K, Schewe T, Pütz G, Odünc N, Schäfer G, Siegel E, Geisen U, Abletshauser C, Hoffmann MM.
    Eur J Clin Invest; 2009 Jun; 39(6):463-70. PubMed ID: 19397693
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [Abstract] [Full Text] [Related]

  • 5. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
    Liska B, Khattab AA, Herrmann L, Abdel-Wahab M, Westphal R, Tölg R, Geist V, Richardt G.
    Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
    [Abstract] [Full Text] [Related]

  • 6. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 7. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL.
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [Abstract] [Full Text] [Related]

  • 8. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 9. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J.
    Am Heart J; 2005 Mar 22; 149(3):464-73. PubMed ID: 15864235
    [Abstract] [Full Text] [Related]

  • 10. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Mar 22; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
    Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmölzer I, Wascher TC, März W.
    Eur J Clin Invest; 2010 Mar 22; 40(3):187-94. PubMed ID: 20067513
    [Abstract] [Full Text] [Related]

  • 12. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May 22; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 13. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 22; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 14. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 15; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 16. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators.
    Ann Pharmacother; 2007 Sep 15; 41(9):1345-51. PubMed ID: 17666579
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
    Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, Ezetimibe/Simvastatin + Fenofibrate Study Group.
    Am Heart J; 2007 Feb 15; 153(2):335.e1-8. PubMed ID: 17239698
    [Abstract] [Full Text] [Related]

  • 18. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M, Volpe M, Massaad R, Davies MJ, Allen C.
    Int J Cardiol; 2005 Jul 10; 102(2):327-32. PubMed ID: 15982505
    [Abstract] [Full Text] [Related]

  • 19. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
    Feldman T, Koren M, Insull W, McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y.
    Am J Cardiol; 2004 Jun 15; 93(12):1481-6. PubMed ID: 15194017
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR.
    Am J Cardiol; 2008 Feb 15; 101(4):490-6. PubMed ID: 18312764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.